The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health•

Tag: Regulatory

Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development
Clinical & Manufacturing

Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development

OCT 16, 2026
New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia
Clinical & Manufacturing

New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia

SEP 24, 2026
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
Clinical & Manufacturing

MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination

SEP 18, 2026
Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health
Finance

Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health

SEP 16, 2026
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Infectious Disease & AMR

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

SEP 15, 2026